F
Foghorn Therapeutics Inc (FHTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$1.79
-0.28 (-13.53%)
Market Cap: $124.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Foghorn Therapeutics Inc (FHTX) P/E Ratio & Valuation Multiples
Foghorn Therapeutics (FHTX) trades at 40.1x trailing earnings and 1.1x sales. Its P/S of 1.1x is below its 5-year median of 11.9x.
Current Multiples
Its enterprise value is 19.9x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | 40.1x |
| Forward P/E | N/A |
| Price to sales | 1.1x |
| EV/EBITDA | 19.9x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.1x | 11.9x | N/A |
Valuation History
Over the 6 year ends shown, its P/S ranged from 7.9x in 2023 to 640.0x in 2021.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $5.40 | 11.0x | N/A |
| 2024 | $4.72 | 11.2x | N/A |
| 2023 | $6.45 | 7.9x | N/A |
| 2022 | $6.38 | 13.8x | N/A |
| 2021 | $22.87 | 640.0x | 8.7x |
| 2020 | $20.27 | 469.1x | 2.7x |
Frequently Asked Questions About FHTX
What is FHTX's price to sales ratio?
Foghorn Therapeutics has a price to sales ratio of 1.1x.
FHTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors